The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
GCLLSG 2016 | Selinexor for CLL – mechanism of action and combination with ibrutinib
Jennifer Woyach, MD of The Ohio State University Comprehensive Cancer Center, Columbus, OH talks about selinexor for chronic lymphocytic leukemia (CLL) at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Selinexor is an inhibitor of XPO1, which has been shown to be overactive in a number of cancers, including CLL. Dr Woyach explains that an inhibitor for XPO1 appears to reduce BTK protein expression and downstream B-cell receptor (BCR) signaling. They are interested in combining it with ibrutinib or other BTK inhibitors; there is a trial assessing this combination (NCT02303392).
